Eir Ventures are delighted to announce our most recent investment in GutCRINE. The company is a pioneering spin out from Copenhagen University developing a new first in class therapy targeting metabolic and age-related diseases like obesity, type 2 diabetes, osteoporosis and Parkinson’s disease.
Eir invests in GutCRINE
